Translational Development Acquisition Corp. Units
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Translational Development Acquisition Corp. Units (TDACU) - Net Assets
Latest net assets as of September 2025: $173.52 Million USD
Based on the latest financial reports, Translational Development Acquisition Corp. Units (TDACU) has net assets worth $173.52 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($179.98 Million) and total liabilities ($6.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $173.52 Million |
| % of Total Assets | 96.41% |
| Annual Growth Rate | 257.39% |
| 5-Year Change | 146.4% |
| 10-Year Change | N/A |
| Growth Volatility | 388366.99 |
Translational Development Acquisition Corp. Units - Net Assets Trend (2017–2024)
This chart illustrates how Translational Development Acquisition Corp. Units's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Translational Development Acquisition Corp. Units (2017–2024)
The table below shows the annual net assets of Translational Development Acquisition Corp. Units from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $168.75 Million | +33341.43% |
| 2023-12-31 | $-507.66K | -2196.26% |
| 2022-12-31 | $-22.11K | -100.04% |
| 2020-12-31 | $54.23 Million | -20.82% |
| 2019-12-31 | $68.49 Million | -66.28% |
| 2018-12-31 | $203.08 Million | +896832.76% |
| 2017-12-31 | $22.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Translational Development Acquisition Corp. Units's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 559567800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.33 Billion | 10860.27% |
| Other Comprehensive Income | $16.88 Billion | 10002.80% |
| Total Equity | $168.75 Million | 100.00% |
Translational Development Acquisition Corp. Units Competitors by Market Cap
The table below lists competitors of Translational Development Acquisition Corp. Units ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Planet Technology
TWO:6263
|
$140.80 Million |
|
Jiangsu Smartwin Electronics Technology Co.Ltd.
SHE:301106
|
$140.83 Million |
|
Kyobo Securiti
KO:030610
|
$140.83 Million |
|
SPARX Group Co. Ltd
PINK:SRXXF
|
$140.83 Million |
|
Lotus Technology Inc.
NASDAQ:LOT
|
$140.77 Million |
|
Tang Eng Iron Works Co Ltd
TWO:2035
|
$140.72 Million |
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
$140.71 Million |
|
Meridian Mining UK Societas
OTCQX:MRRDF
|
$140.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Translational Development Acquisition Corp. Units's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -507,658 to 168,752,776, a change of 169,260,434.
- Net loss of 71,012 reduced equity.
- Dividend payments of 125,346 reduced retained earnings.
- New share issuances of 169,050,000 increased equity.
- Other comprehensive income increased equity by 16,880,000,000.
- Other factors decreased equity by 16,879,593,208.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-71.01K | -0.04% |
| Dividends Paid | $125.35K | -0.07% |
| Share Issuances | $169.05 Million | +100.18% |
| Other Comprehensive Income | $16.88 Billion | +10002.8% |
| Other Changes | $-16.88 Billion | -10002.56% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Translational Development Acquisition Corp. Units's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 12129.55x to 0.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $10.44 | x |
| 2018-12-31 | $35.28 | $10.44 | x |
| 2019-12-31 | $9.64 | $10.44 | x |
| 2020-12-31 | $7.44 | $10.44 | x |
| 2022-12-31 | $-0.01 | $10.44 | x |
| 2023-12-31 | $-0.13 | $10.44 | x |
| 2024-12-31 | $41.67 | $10.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Translational Development Acquisition Corp. Units utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.00%
- • Asset Turnover: 6090.20x
- • Equity Multiplier: 1.04x
- Recent ROE (-0.04%) is below the historical average (0.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -1.71% | 0.00% | 0.00x | 24.19x | $-2.65K |
| 2018 | 0.69% | 200.77% | 0.00x | 1.03x | $-18.90 Million |
| 2019 | 3.70% | 0.00% | 0.00x | 1.09x | $-4.32 Million |
| 2020 | -1.49% | 0.00% | 0.00x | 1.19x | $-6.23 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-68.45K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-434.78K |
| 2024 | -0.04% | 0.00% | 6090.20x | 1.04x | $-16.95 Million |
Industry Comparison
This section compares Translational Development Acquisition Corp. Units's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Translational Development Acquisition Corp. Units (TDACU) | $173.52 Million | -1.71% | 0.04x | $140.79 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |